Search | Clinical Trials Finder

Conditions: Prostatic Hyperplasia
Interventions: Treatment sequence A, Treatment sequence B, Treatment sequence C; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Invasive Carcinoma, In Situ Carcinoma, Fibrocystic Changes, Atypical Ductal Hyperplasia
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: CAH - Congenital Adrenal Hyperplasia
Interventions: Crinecerfont; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 14 Years to 17 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: San Diego, California • Aurora, Colorado • Ann Arbor, Michigan + 3 more

Conditions: Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions: Acolbifene Hydrochloride, Biospecimen Collection, Mammography, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 35 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Duarte, California • Chicago, Illinois • Kansas City, Kansas + 1 more

Conditions: Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With Atypia, Endometrial Intraepithelial Neoplasia
Interventions: Not listed
Lead sponsor: Exact Sciences Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 4,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Sarasota, Florida • Scarborough, Maine • Murfreesboro, Tennessee + 1 more

Conditions: Prostatic Hyperplasia
Interventions: Embosphere Microspheres; Device
Lead sponsor: South Florida Medical Imaging, PA; Other
Eligibility: 40 Years to 89 Years · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Congenital Adrenal Hyperplasia
Interventions: Abiraterone acetate, Placebo, Hydrocortisone, Fludrocortisone; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 2 Years to 9 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more

Conditions: Prostatic Hyperplasia
Interventions: Polyphenon E, Placebo; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 30 Years to 80 Years · Male only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 10
States / cities: Gainesville, Florida • Jacksonville, Florida • Lakeland, Florida + 5 more

Conditions: Benign Prostatic Hyperplasia
Interventions: ProTouch Laser Enucleation of Prostate (LEP), Transurethral Resection of Prostate (TURP); Procedure
Lead sponsor: Boston University; Other
Eligibility: 50 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Benign Prostatic Hyperplasia
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 40 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 8
States / cities: Newport Beach, California • Tarzana, California • Middlebury, Connecticut + 5 more

Conditions: Prostatic Hyperplasia, Prostatic Hypertrophy, Benign
Interventions: Doxazosin, Finasteride, Doxazosin placebo, Finasteride placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 50 Years and older · Male only
Enrollment: 3,407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2001
U.S. locations: 17
States / cities: La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 13 more

Conditions: Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Interventions: Everolimus, Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System; Drug · Other · Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 18
States / cities: Greeley, Colorado • Loveland, Colorado • Honolulu, Hawaii + 11 more

Conditions: Benign Prostatic Hyperplasia
Interventions: Urocross implant, Sham-control; Device · Diagnostic Test
Lead sponsor: Prodeon Medical, Inc; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: Maywood, Illinois • Roanoke, Virginia

Conditions: Benign Prostatic Hyperplasia With Outflow Obstruction, Urinary Retention, Lower Urinary Tract Symptoms
Interventions: Preoperative pelvic floor physical therapy; Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer, Head and Neck Cancer, Diffuse Large B-cell Lymphoma
Interventions: PET/CT, Laboratory Testing, Safety Testing, Immunohistochemistry staining, F-18-ISO; Radiation · Other · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Congenital Adrenal Hyperplasia
Interventions: Hydrocortisone; Drug
Lead sponsor: Neurocrine UK Limited; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer, Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)
Interventions: BOTOX; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 50 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions: Not listed
Lead sponsor: Société Internationale d'Urologie; Other
Eligibility: 18 Years and older · Male only
Enrollment: 7,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
Interventions: Zenflow Spring System, Sham Procedure; Device
Lead sponsor: Zenflow, Inc.; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Glenview, Illinois • Las Vegas, Nevada + 3 more

Conditions: Atypical Ductal Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Interventions: metformin hydrochloride, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 25 Years to 55 Years · Female only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 27
States / cities: Duarte, California • Los Angeles, California • South Pasadena, California + 18 more

Conditions: Hyperplasia, Stenosis
Interventions: angioplasty, stent placement; Procedure
Lead sponsor: National Kidney Foundation, United States; Other
Eligibility: 19 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Congenital Adrenal Hyperplasia
Interventions: Chronocort®, Standard Care; Drug
Lead sponsor: Neurocrine UK Limited; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Morehead City, North Carolina

Conditions: Benign Prostatic Hypertrophy (BPH), Lower Urinary Track Symptoms
Interventions: Survey using a questionnaire.; Other
Lead sponsor: Benaroya Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Surgical Complication, Paresthesia, Fracture, Nerve Injury, Nerve Entrapments, Mandibular Nerve Injuries, Mandibular Hypoplasia, Mandibular Retrognathism, Mandibular Hyperplasia, Mandibular Prognathism
Interventions: Sonopet ultrasonic saw, Reciprocating saw; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 45 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: San Francisco, California

Search by objective public record fields.

Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States

X-Ray Mammography Standard of Care Protocol

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Endometrial Cancer Vaginal Fluid Specimen Collection Study

Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams

Androgen Reduction in Congenital Adrenal Hyperplasia

Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia

Laser Enucleation of Prostate (LEP) Versus Transurethral Resection of Prostate (TURP)

Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Medical Therapy of Prostatic Symptoms

Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

Expander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval Sheath

Preoperative Pelvic Floor Physical Therapy to Minimize Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate

Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1

A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH

BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)

BPH Global Registry

Safety and Effectiveness Study of the Zenflow Spring System

Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

Stent vs. Angioplasty for Treatment of Thrombosed AV Grafts: Long-Term Outcomes

Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms

Trial of Bilateral Sagittal Split Osteotomy Induced Paresthesia Using Ultrasonic vs. Reciprocating Saw Instrumentation